Celularity announced that the company received notification from Nasdaq stating that because the company has not yet filed its Form 10-Q for the quarter ended March 31 and because the company remains delinquent in filing its Annual Report on Form 10-K for the year ended December 31, 2023, does not comply with the Nasdaq continued listing requirements which require listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission. Nasdaq’s notice has no immediate effect on the listing of Celularity’s common stock and warrants, which continue to trade on Nasdaq.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CELU:
- Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
- Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy
- Celularity announces publication on benefits of placental circulating T cells
- Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
- Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024